Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (511)	2/2/1998 8:04:00 AM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 756

A Yahoo post some time ago attributed to Rafick Henein the CEO of Zenith Goldline that clozaril was difficult to reformulate. Looks like that fits in with what Bethune is saying in the article. <<cancer drugs>> except for paxene I don't know what they are working on. I don't blame them for not saying. I hope they are working on something. "Made-from scratch" sounds like biscuits. I can see Frost in the laboratory with flour up to his elbows. This strategy does appear to have promise. It would only take the 12 approvals and a blockbuster to get us back to $10-$11. Jackson